Retrospective analysis of our cases with sudden hearing loss.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects*; D002648:Child; D003911:Dextrans / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D003639:Hearing Loss, Sudden / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000925:Anticoagulants; D003911:Dextrans; D005938:Glucocorticoids; D014665:Vasodilator Agents; D010208:Papaverine; D003975:Diazepam; D010431:Pentoxifylline; D008775:Methylprednisolone